Skip to content

Supplier News

Alvogen to acquire four products from Pfizer

Alvogen to acquire four products from Pfizer

Alvogen has entered an agreement to buy a portfolio of four U.S. pharmaceutical products from Pfizer Inc. Under the deal announced Wednesday, Alvogen plans to acquire three injectable products — Clindamycin, Voriconazole and Melphalan — and one inhaled solution product, Acetylcysteine.

Heartland to buy Splenda brand from J&J

Heartland to buy Splenda brand from J&J

Heartland Food Products Group plans to acquire the Splenda low-calorie sweetener brand from McNeil Nutritionals LLC, a subsidiary of Johnson & Johnson Consumer Inc. Financial terms of the agreement weren’t disclosed. Heartland said the transaction is slated to close before the end of this year.

Upsher-Smith promotes Field to president

Upsher-Smith promotes Field to president

Rusty Field, chief commercial officer at Upsher-Smith Laboratories Inc., has been appointed as president of the company. Upsher-Smith said Monday that in the new role, Field will be responsible for delivering revenue and profitability to meet the pharmaceutical company’s growth objectives.

Switches will continue to be pacesetters in O-T-C arena

Switches will continue to be pacesetters in O-T-C arena

Growth of the U.S. over-the-counter medications market has been primarily driven by prescription-to-OTC switches And that expansion is likely to continue. Due to an increasingly favorable regulatory environment, Kline & Co.

Camber rolls out Baraclude generic

Camber rolls out Baraclude generic

Camber Pharmaceuticals Inc. has launched entecavir tablets, an antiviral medication. Camber said Friday that its entecavir product is available in 30- and 90-count bottle for the 0.5-mg strength and in 30-count bottles for the 1-mg dosage.

Galderma ships Epiduo Forte Gel

Galderma ships Epiduo Forte Gel

Galderma Laboratories has released Epiduo Forte Gel, a once-daily topical acne treatment, to retail pharmacies nationwide and in Puerto Rico. The medication, adapalene and benzoyl peroxide 0.3%/2.5%, received Food and Drug Administration approval last month.